0.10Open0.10Pre Close28 Volume1.06K Open Interest2.50Strike Price282.00Turnover65.88%IV12.45%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.3495Delta1.0716Gamma31.07Leverage Ratio-0.0036Theta0.0004Rho10.86Eff Leverage0.0019Vega
Oramed Pharmaceuticals Stock Discussion
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Tuesday, 11th February at 9:15 am
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities
Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.
OraTech will have global marketing rights to Oramed's POD™ or...
Oral Insulin Breakthrough: $75M Deal Positions Oramed's Revolutionary Drug Delivery Platform for Global Launch
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Compa...
your turn tonight?
No comment yet